» Articles » PMID: 35215346

AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications

Overview
Publisher MDPI
Specialty Chemistry
Date 2022 Feb 26
PMID 35215346
Authors
Affiliations
Soon will be listed here.
Abstract

With the development of Ga and Lu radiochemistry, theranostic approaches in modern nuclear medicine enabling patient-centered personalized medicine applications have been growing in the last decade. In conjunction with the search for new relevant molecular targets, the design of innovative chelating agents to easily form stable complexes with various radiometals for theranostic applications has gained evident momentum. Initially conceived for magnetic resonance imaging applications, the chelating agent AAZTA features a mesocyclic seven-membered diazepane ring, conferring some of the properties of both acyclic and macrocyclic chelating agents. Described in the early 2000s, AAZTA and its derivatives exhibited interesting properties once complexed with metals and radiometals, combining a fast kinetic of formation with a slow kinetic of dissociation. Importantly, the extremely short coordination reaction times allowed by AAZTA derivatives were particularly suitable for short half-life radioelements (i.e., Ga). In view of these particular characteristics, the scope of this review is to provide a survey on the design, synthesis, and applications in the nuclear medicine/radiopharmacy field of AAZTA-derived chelators.

Citing Articles

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues.

Ioannidis I, Lefkaritis G, Georgiades S, Pashalidis I, Kontoghiorghes G Int J Mol Sci. 2024; 25(11).

PMID: 38892142 PMC: 11173192. DOI: 10.3390/ijms25115954.


Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy.

Souche C, Fouillet J, Rubira L, Donze C, Deshayes E, Fersing C Int J Mol Sci. 2024; 25(1).

PMID: 38203632 PMC: 10779041. DOI: 10.3390/ijms25010462.


Scandium Radioisotopes-Toward New Targets and Imaging Modalities.

Kilian K, Pyrzynska K Molecules. 2023; 28(22).

PMID: 38005390 PMC: 10675654. DOI: 10.3390/molecules28227668.


From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [Ga]Ga-DATA.SA.FAPi.

Greifenstein L, Kramer C, Moon E, Rosch F, Klega A, Landvogt C Pharmaceuticals (Basel). 2022; 15(8).

PMID: 36015148 PMC: 9415298. DOI: 10.3390/ph15081000.

References
1.
Fernandez R, Eppard E, Lehnert W, Jimenez-Franco L, Soza-Ried C, Ceballos M . Evaluation of Safety and Dosimetry of Lu-DOTA-ZOL for Therapy of Bone Metastases. J Nucl Med. 2021; 62(8):1126-1132. PMC: 8833870. DOI: 10.2967/jnumed.120.255851. View

2.
Aime S, Calabi L, Cavallotti C, Gianolio E, Giovenzana G, Losi P . [Gd-AAZTA]-: a new structural entry for an improved generation of MRI contrast agents. Inorg Chem. 2004; 43(24):7588-90. DOI: 10.1021/ic0489692. View

3.
Sinnes J, Nagel J, Rosch F . AAZTA/AAZTA-TOC: synthesis and radiochemical evaluation with Ga, Sc and Lu. EJNMMI Radiopharm Chem. 2019; 4(1):18. PMC: 6675801. DOI: 10.1186/s41181-019-0068-1. View

4.
Waldron B, Parker D, Burchardt C, Yufit D, Zimny M, Roesch F . Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68. Chem Commun (Camb). 2012; 49(6):579-81. DOI: 10.1039/c2cc37544c. View

5.
Simecek J, Schulz M, Notni J, Plutnar J, Kubicek V, Havlickova J . Complexation of metal ions with TRAP (1,4,7-triazacyclononane phosphinic acid) ligands and 1,4,7-triazacyclononane-1,4,7-triacetic acid: phosphinate-containing ligands as unique chelators for trivalent gallium. Inorg Chem. 2012; 51(1):577-90. DOI: 10.1021/ic202103v. View